Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
Clinical Lymphoma Myeloma and Leukemia · 2023-10 · 23 (10) · 742-748
DOI: 10.1016/j.clml.2023.05.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023-10. Verfasst von Georgina Gener-Ricos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Chronic-Phase, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Dasatinib is a BCR::ABL1 tyrosine kinase inhibitor approved as frontline therapy at a 100 mg daily for chronic myeloid leukemia in chronic phase (CML-CP). The use of a lower dose of dasatinib (50 mg daily) has demonstrated better tolerance and improved outcomes compared with the standard dose. Here, we report the updated results in a large cohort with a 5-year follow-up. PATIENTS AND METHODS: Patients with newly diagnosed CML-CP were eligible. Entry and response-outcome criteria were standard. Dasatinib was given as 50 mg orally daily. RESULTS: Eighty-three patients were included. At 3 months, 78 (96%) patients achieved BCR::ABL1 transcripts (IS) ≤10%, and at 12 months, 65 (81%) patients achieved BCR::ABL1 transcript (IS) ≤0.1%. The cumulative incidence of complete cytogenetic, major molecular, and deep molecular responses at 5 years were 98%, 95%, and 82%, respectively. Rates of failures due to resistance (n = 4; 5%) and toxicity (n = 4; 5%) were low. The 5-year overall survival was 96% and event-free survival 90%. No transformations to accelerated or blastic phase were observed. Grade 3 to 4 pleural effusions developed in 2% of patients. CONCLUSION: Dasatinib 50 mg daily is an effective and safe treatment for newly diagnosed CML-CP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: hkantarjian@mdanderson.org.
Zitieren
APA
Gener-Ricos, G., Haddad, F. G., Sasaki, K., Issa, G. C., Skinner, J., Masarova, L., Borthakur, G., Alvarado, Y., Garcia-Manero, G., Jabbour, E., & Kantarjian, H. (2023). Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clinical Lymphoma Myeloma and Leukemia, 23(10), 742-748. https://doi.org/10.1016/j.clml.2023.05.009
Vancouver
Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, et al. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clinical Lymphoma Myeloma and Leukemia. 2023;23(10):742-748. doi:10.1016/j.clml.2023.05.009
BibTeX
@article{GenerRicos2023,
author = {Gener-Ricos, Georgina and Haddad, Fadi G and Sasaki, Koji and Issa, Ghayas C and Skinner, Jeffrey and Masarova, Lucia and Borthakur, Gautam and Alvarado, Yesid and Garcia-Manero, Guillermo and Jabbour, Elias and Kantarjian, Hagop},
title = {Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
volume = {23},
number = {10},
pages = {742--748},
doi = {10.1016/j.clml.2023.05.009}
}
EUVIMED